Your Shopping Cart Is Empty
| Report Code: A11783 | Feb 2022 | Pages: 307 | ||
| Tables: 179 | Charts: 56 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Single Cell Multiomics Market
Request Now !The global single cell multiomics market size was valued at $2,175 million in 2020, and is projected to reach $15,261.19 million by 2030, registering a CAGR of 21.4% from 2021 to 2030. Single cell multiomics technologies typically measure multiple types of molecules from the same individual cell, allowing for more in-depth biological insight than can be gained by analyzing each molecular layer from separate cells. Single-cell multimodal omics (scMulti-omics) technologies allow for the measurement of multiple modalities from the same cell, including DNA methylation, chromatin accessibility, RNA expression, protein abundance, gene perturbation, and spatial information, unlike live-cell fluorescence imaging, which involves the destruction of cells for analysis.
Integrated techniques combine individual omics data in a sequential or simultaneous manner to understand the interplay of molecules. The single cell sequencing technology is classified as genotypic and phenotypic, which aid in determining the mechanisms that govern diseases and health. Furthermore, single cell multiomics market applications primarily include oncology, cell biology, neurology, stem cell, and immunology. Single cell omics has enormous potential for deciphering virus biology and virus-host cell interactions, making it a powerful tool in virology that should be used more frequently in the future.
The growth of the single cell multiomics market is majorly driven by technological advancements in single-cell analysis products and rise in number of large-scale genomics studies leveraging single-cell RNA Sequencing (sc-RNA). Furthermore, rising disposable income in emerging nations as well as increasing adoption of personalized medicine for screening and diagnostics of genetic disorders, are driving the growth of the single cell multiomics market. Personalized medicine can bring more clarity to the clinical and biological complexity of these types of disorders associated with high mortality and enormous health care costs. Furthermore, this might provide valuable tools for preventive strategies as well as possible clues on the disease's evolution, and it could aid in predicting morbidity, mortality, and detecting chronic disease indicators much earlier in the disease's course.
In addition, new single-cell platforms facilitate separation and analysis, and in some cases, both the potential development and limitations of these technologies are rapidly being developed, resulting in increased interest among researchers, particularly in the field of single cell genomics. As a result, technological advancements in single-cell analysis products is expected to drive the single cell multiomics market growth even further.
Furthermore, increase in various initiatives, collaborations among pharmaceutical and biotechnological companies and research institutes play a pivotal role and thus, further boost the market growth. However, the high cost of single cell analysis and the scarcity of large online data storage and analysis platforms are expected to limit the market growth. Expansion into new research applications, such as single-cell metabolomics, and increased collaborations and funding in single cell multiomics research, on the other hand, are expected to provide lucrative growth opportunities for single cell multiomics market players.
Moreover, considerable rise in healthcare expenditure worldwide has further fueled the market. The major factors that are responsible for increase in healthcare expenditure are rise in population, especially geriatric and increased medical service utilization for early diagnosis of genetic disorders.
In addition, the COVID-19 outbreak is anticipated to have a positive impact on the single cell multiomics market. A huge number of clinics and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. The non-essential procedures took a potential backlog due to rapidly rising COVID-19 cases. The lockdown led to the disruption of manufacturing and transportation of healthcare essentials. Moreover, other factors responsible for the impact on the market include limited availability of medical care, shortage of healthcare staff and rise in burden of COVID-19 related hospitalization.
Furthermore, there has been a positive impact on a variety of healthcare services, including single cell multiomics. According to healthcare experts, the single cell multiomics market is one of the most rapidly evolving markets. Furthermore, rising chronic diseases such as cancer and infectious diseases caused by viruses are driving the global market. The study of single cell multiomics for COVID-19 may pave the way for the target market to expand.
Accordingly, untapped, emerging markets are expected to offer potential growth opportunities, due to improved healthcare infrastructure, surge in personalization of medicines, increase in unmet healthcare needs, and rise in R&D activities. In addition, various technological advancements for early diagnosis of diseases is an emerging opportunity for key players to invest in the single cell multiomics market.
The global single cell multiomics market is segmented on the basis of type, application, technique, end user, and region. On the basis of type, the market is categorized into single cell genomics, single cell proteomics, single cell transcriptomics, and single cell metabolomics. By application, it is classified into oncology, cell biology, neurology, immunology and stem cell research. By technique, it is divided into single cell isolation & dispensing and single cell analysis. By end user, it is segmented into academic institutes, contract research organizations and pharmaceutical & biotech companies.
Region wise, the single cell multiomics market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia and rest of LAMEA).
Based on type, the single cell genomics segment held the largest share in the global single cell multiomics market in 2020 owing to advanced method of classifying individual cells that can define unique traits and identify rare cell types.
On the basis of application, the oncology segment held the largest market share in 2020 and is expected to remain dominant during the forecast period owing to rise in cancer cases globally, demand for personalization of treatments, surge in early diagnosis and screening among the population.
On the basis of technique, the single-cell analysis held the largest market share in 2020 and is expected to remain dominant during the forecast period owing to its fast, effective, and gentle to maintain the native expression profiles advantage.
On the basis of end user, the academic institutes segment held the largest single cell multiomics market share in 2020 and is expected to remain dominant during the forecast period, owing to surge in number of ongoing research projects at academia and research laboratories.
North America is projected to account for a major share of the global single cell multiomics market during the forecast period. The market in the region is anticipated witness growth in future, owing to availability of developed healthcare infrastructure and continuous research activities for the development of advanced technologies in the region. Europe holds the second largest share and is expected to witness highest CAGR during the forecast period. Moreover, Germany and UK are expected to grow at high CAGR in Europe single cell multiomics market.
The major players profiled in the report are 10x Genomics, Inc., Becton, Dickinson and Company, Berkeley Lights Inc., BGI Genomics Co. Ltd, Bio Rad Laboratories, Inc., Danaher Corporation (Cytiva Life Sciences), Dolomite Bio, Epicypher Inc., Fluidigm Corporation, Illimina, Inc, Miltenyi Biotec B.V. & CO., Mission Bio, Inc., Nanostring Technologies, Inc., Olink Holding AB (Olink Proteomics), Parse Bioscience, Qiagen N.V., Takara Holdings Inc. (Takara Bio Group) and Thermo Fischer Scientific Inc.
Key Benefits for Stakeholders
Single Cell Multiomics Market Report Highlights
| Aspects | Details |
|---|---|
| By Type |
|
| By Application |
|
| By Technique |
|
| By End User |
|
| By Region |
|
| By KEY MARKET PLAYERS |
|
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Technological advancements in single-cell analysis products
3.5.1.2.Increase in adoption of personalized medicine for screening and diagnostics of genetic disorders
3.5.2.Restraints
3.5.2.1.High cost of single-cell analysis products
3.5.2.2.Dearth of skilled professionals
3.5.3.Opportunity
3.5.3.1.Increase in funding in the research of single cell multiomics
3.5.4.Impact analysis
3.6.Clinical use case of single cell multiomics analysis
3.7.COVID-19 impact analysis on the single cell multiomics market
CHAPTER 4:SINGLE CELL MULTIOMICS MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Single cell genomics
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Single cell proteomics
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Single cell transcriptomics
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Single cell metabolomics
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
CHAPTER 5:SINGLE CELL MULTIOMICS MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Oncology
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Cell biology
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.Neurology
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.5.Immunology
5.5.1.Market size and forecast
5.5.2.Market analysis, by country
5.6.Stem cell research
5.6.1.Market size and forecast
5.6.2.Market analysis, by country
CHAPTER 6:SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE
6.1.Overview
6.1.1.Market size and forecast
6.2.Single-cell isolation and dispensing
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Single-cell analysis
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
CHAPTER 7:SINGLE CELL MULTIOMICS MARKET, BY END USER
7.1.Overview
7.1.1.Market size and forecast
7.2.Academic institutes
7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country
7.3.Contract research organizations
7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country
7.4.Pharmaceutical and biotech companies
7.4.1.Market size and forecast, by region
7.4.2.Market analysis, by country
CHAPTER 8:SINGLE CELL MULTIOMICS MARKET, BY REGION
8.1.Overview
8.1.1.Market size and forecast
8.2.North America
8.2.1.Key market trends, growth factors, and opportunities
8.2.2.North America market size and forecast, by type
8.2.3.North America market size and forecast, by application
8.2.4.North America market size and forecast, by technique
8.2.5.North America market size and forecast, by end user
8.2.6.Market size and forecast, by country
8.2.6.1.U.S.
8.2.6.1.1.U.S. single cell multiomics market, by type
8.2.6.1.2.U.S. single cell multiomics market, by application
8.2.6.1.3.U.S. single cell multiomics market, by technique
8.2.6.1.4.U.S. Single cell multiomics market, by end user
8.2.6.2.Canada
8.2.6.2.1.Canada single cell multiomics market, by type
8.2.6.2.2.Canada single cell multiomics market, by application
8.2.6.2.3.Canada single cell multiomics market, by technique
8.2.6.2.4.Canada single cell multiomics market, by end user
8.2.6.3.Mexico
8.2.6.3.1.Mexico single cell multiomics market, by type
8.2.6.3.2.Mexico single cell multiomics market, by application
8.2.6.3.3.Mexico single cell multiomics market, by technique
8.2.6.3.4.Mexico single cell multiomics market, by end user
8.3.Europe
8.3.1.Key market trends, growth factors, and opportunities
8.3.2.Europe market size and forecast, by type
8.3.3.Europe market size and forecast, by application
8.3.4.Europe market size and forecast, by technique
8.3.5.Europe market size and forecast, by end user
8.3.6.Market size and forecast, by country
8.3.6.1.Germany
8.3.6.1.1.Germany single cell multiomics market, by type
8.3.6.1.2.Germany single cell multiomics market, by application
8.3.6.1.3.Germany single cell multiomics market, by technique
8.3.6.1.4.Germany single cell multiomics market, by end user
8.3.6.2.France
8.3.6.2.1.France single cell multiomics market, by type
8.3.6.2.2.France single cell multiomics market, by application
8.3.6.2.3.France single cell multiomics market, by technique
8.3.6.2.4.France single cell multiomics market, by end user
8.3.6.3.UK
8.3.6.3.1.UK single cell multiomics market, by type
8.3.6.3.2.UK single cell multiomics market, by application
8.3.6.3.3.UK single cell multiomics market, by technique
8.3.6.3.4.UK single cell multiomics market, by end user
8.3.6.4.Italy
8.3.6.4.1.Italy single cell multiomics market, by type
8.3.6.4.2.Italy single cell multiomics market, by application
8.3.6.4.3.Italy single cell multiomics market, by technique
8.3.6.4.4.Italy single cell multiomics market, by end user
8.3.6.5.Spain
8.3.6.5.1.Spain single cell multiomics market, by type
8.3.6.5.2.Spain single cell multiomics market, by application
8.3.6.5.3.Spain single cell multiomics market, by technique
8.3.6.5.4.Spain single cell multiomics market, by end user
8.3.6.6.Rest of Europe
8.3.6.6.1.Rest of Europe single cell multiomics market, by type
8.3.6.6.2.Rest of Europe single cell multiomics market, by application
8.3.6.6.3.Rest of Europe single cell multiomics market, by technique
8.3.6.6.4.Rest of Europe single cell multiomics market, by end user
8.4.Asia-Pacific
8.4.1.Key market trends, growth factors, and opportunities
8.4.2.Asia-Pacific market size and forecast, by type
8.4.3.Asia-Pacific market size and forecast, by application
8.4.4.Asia-Pacific market size and forecast, by technique
8.4.5.Asia-Pacific market size and forecast, by end user
8.4.6.Market size and forecast, by country
8.4.6.1.Japan
8.4.6.1.1.Japan single cell multiomics market, by type
8.4.6.1.2.Japan single cell multiomics market, by application
8.4.6.1.3.Japan single cell multiomics market, by technique
8.4.6.1.4.Japan single cell multiomics market, by end user
8.4.6.2.China
8.4.6.2.1.China single cell multiomics market, by type
8.4.6.2.2.China single cell multiomics market, by application
8.4.6.2.3.China single cell multiomics market, by technique
8.4.6.2.4.China single cell multiomics market, by end user
8.4.6.3.Australia
8.4.6.3.1.Australia single cell multiomics market, by type
8.4.6.3.2.Australia single cell multiomics market, by application
8.4.6.3.3.Australia single cell multiomics market, by technique
8.4.6.3.4.Australia single cell multiomics market, by end user
8.4.6.4.India
8.4.6.4.1.India single cell multiomics market, by type
8.4.6.4.2.India single cell multiomics market, by application
8.4.6.4.3.India single cell multiomics market, by technique
8.4.6.4.4.India single cell multiomics market, by end user
8.4.6.5.South Korea
8.4.6.5.1.South Korea single cell multiomics market, by type
8.4.6.5.2.South Korea single cell multiomics market, by application
8.4.6.5.3.South Korea single cell multiomics market, by technique
8.4.6.5.4.South Korea single cell multiomics market, by end user
8.4.6.6.Rest of Asia-Pacific
8.4.6.6.1.Rest of Asia-Pacific single cell multiomics market, by type
8.4.6.6.2.Rest of Asia-Pacific single cell multiomics market, by application
8.4.6.6.3.Rest of Asia-Pacific single cell multiomics market, by technique
8.4.6.6.4.Rest of Asia-Pacific single cell multiomics market, by end user
8.5.LAMEA
8.5.1.Key market trends, growth factors, and opportunities
8.5.2.LAMEA market size and forecast, by type
8.5.3.LAMEA market size and forecast, by application
8.5.4.LAMEA market size and forecast, by technique
8.5.5.LAMEA market size and forecast, by end user
8.5.6.Market size and forecast, by country
8.5.6.1.Brazil
8.5.6.1.1.Brazil single cell multiomics market, by type
8.5.6.1.2.Brazil single cell multiomics market, by application
8.5.6.1.3.Brazil single cell multiomics market, by technique
8.5.6.1.4.Brazil Single cell multiomics market, by end user
8.5.6.2.Saudi Arabia
8.5.6.2.1.Saudi Arabia single cell multiomics market, by type
8.5.6.2.2.Saudi Arabia single cell multiomics market, by application
8.5.6.2.3.Saudi Arabia single cell multiomics market, by technique
8.5.6.2.4.Saudi Arabia single cell multiomics market, by end user
8.5.6.3.Rest of LAMEA
8.5.6.3.1.Rest of LAMEA single cell multiomics market, by type
8.5.6.3.2.Rest of LAMEA single cell multiomics market, by application
8.5.6.3.3.Rest of LAMEA single cell multiomics market, by technique
8.5.6.3.4.Rest of LAMEA single cell multiomics market, by end user
CHAPTER 9:COMPANY PROFILES
9.1.10X GENOMICS, INC.
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Business performance
9.1.6.Key strategic moves and developments
9.2.BECTON, DICKINSON, AND COMPANY
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments
9.3.BERKLEY LIGHTS INC.
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.3.6.Key strategic moves and developments
9.4.BGI GENOMICS CO. LTD.
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.4.5.Business performance
9.4.6.Key strategic moves and developments
9.5.BIO-RAD LABORATORIES, INC.
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance
9.5.6.Key strategic moves and developments
9.6.DANAHER CORPORATION (CYTIVA LIFE SCIENCES)
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.6.6.Key strategic moves and developments
9.7.DOLOMITE BIO
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Key strategic moves and developments
9.8.EPICYPHER, INC.
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Key strategic moves and developments
9.9.FLUIDIGM CORPORATION
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.9.6.Key strategic moves and developments
9.10.ILLIMINA, INC.
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance
9.11.MILTENYI BIOTEC B.V. & CO. KG
9.11.1.Company overview
9.11.2.Company snapshot
9.11.3.Operating business segments
9.11.4.Product portfolio
9.12.MISSION BIO, INC.
9.12.1.Company overview
9.12.2.Company snapshot
9.12.3.Operating business segments
9.12.4.Product portfolio
9.12.5.Key strategic moves and developments
9.13.NANOSTRING TECHNOLOGIES, INC
9.13.1.Company overview
9.13.2.Company snapshot
9.13.3.Operating business segments
9.13.4.Product portfolio
9.13.5.Business performance
9.13.6.Key strategic moves and developments
9.14.OLINK HOLDING AB (OLINK PROTEOMICS)
9.14.1.Company overview
9.14.2.Company snapshot
9.14.3.Operating business segments
9.14.4.Product portfolio
9.14.5.Key strategic moves and developments
9.15.PARSE BIOSCIENCES
9.15.1.Company overview
9.15.2.Company snapshot
9.15.3.Operating business segments
9.15.4.Product portfolio
9.15.5.Key strategic moves and developments
9.16.QIAGEN N.V.
9.16.1.Company overview
9.16.2.Company snapshot
9.16.3.Operating business segments
9.16.4.Product portfolio
9.16.5.Business performance
9.16.6.Key strategic moves and developments
9.17.TAKARA HOLDINGS INC. (TAKARA BIO GROUP)
9.17.1.Company overview
9.17.2.Company snapshot
9.17.3.Operating business segments
9.17.4.Product portfolio
9.17.5.Business performance
9.17.6.Key strategic moves and developments
9.18.THERMO FISHER SCIENTIFIC, INC.
9.18.1.Company overview
9.18.2.Company snapshot
9.18.3.Operating business segments
9.18.4.Product portfolio
9.18.5.Business performance
9.18.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.GLOBAL SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 02.SINGLE CELL GENOMICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03.SINGLE CELL PROTEOMICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04.SINGLE CELL TRANSCRIPTOMICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05.SINGLE CELL METABOLOMICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06.GLOBAL SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 07.ONCOLOGY MARKET, BY REGION, 2020-2030($MILLION)
TABLE 08.CELL BIOLOGY MARKET, BY REGION, 2020-2030($MILLION)
TABLE 09.NEUROLOGY MARKET, BY REGION, 2020-2030($MILLION)
TABLE 10.IMMUNOLOGY MARKET, BY REGION, 2020-2030($MILLION)
TABLE 11.STEM CELL RESEARCH MARKET, BY REGION, 2020-2030($MILLION)
TABLE 12.GLOBAL SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030($MILLION)
TABLE 13.SINGLE-CELL ISOLATION AND DISPENSING MARKET, BY REGION, 2020-2030($MILLION)
TABLE 14.SINGLE-CELL ANALYSIS MARKET, BY REGION, 2020-2030($MILLION)
TABLE 15.GLOBAL SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 16.ACADEMIC INSTITUTES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 17.CONTRACT RESEARCH ORGANIZATIONS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 18.PHARMACEUTICAL AND BIOTECH COMPANIES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 19.GLOBAL SINGLE CELL MULTIOMICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 20.NORTH AMERICA SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 21.NORTH AMERICA SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 22.NORTH AMERICA SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 23.NORTH AMERICA SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 24.NORTH AMERICA SINGLE CELL MULTIOMICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 25.U.S. SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 26.U.S. SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 27.U.S. SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 28.U.S. SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 29.CANADA SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 30.CANADA SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 31.CANADA SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 32.CANADA SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 33.MEXICO SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 34.MEXICO SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 35.MEXICO SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 36.MEXICO SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 37.EUROPE SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 38.EUROPE SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 39.EUROPE SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 40.EUROPE SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 41.EUROPE SINGLE CELL MULTIOMICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 42.GERMANY SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 43.GERMANY SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 44.GERMANY SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 45.GERMANY SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 46.FRANCE SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 47.FRANCE SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 48.FRANCE SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 49.FRANCE SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 50.UK SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 51.UK SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 52.UK SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 53.UK SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 54.ITALY SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 55.ITALY SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 56.ITALY SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 57.ITALY SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 58.SPAIN SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 59.SPAIN SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 60.SPAIN SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 61.SPAIN SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 62.REST OF EUROPE SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 63.REST OF EUROPE SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 64.REST OF EUROPE SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 65.REST OF EUROPE SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 66.ASIA-PACIFIC SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 67.ASIA-PACIFIC SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 68.ASIA-PACIFIC SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 69.ASIA-PACIFIC SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 70.ASIA-PACIFIC SINGLE CELL MULTIOMICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 71.JAPAN SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 72.JAPAN SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 73.JAPAN SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 74.JAPAN SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 75.CHINA SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 76.CHINA SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 77.CHINA SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 78.CHINA SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 79.AUSTRALIA SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 80.AUSTRALIA SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 81.AUSTRALIA SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 82.AUSTRALIA SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 83.INDIA SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 84.INDIA SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 85.INDIA SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 86.INDIA SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 87.SOUTH KOREA SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 88.SOUTH KOREA SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 89.SOUTH KOREA SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 90.SOUTH KOREA SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 91.REST OF ASIA-PACIFIC SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 92.REST OF ASIA-PACIFIC SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 93.REST OF ASIA-PACIFIC SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 94.REST OF ASIA-PACIFIC SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 95.LAMEA SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 96.LAMEA SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 97.LAMEA SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 98.LAMEA SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 99.LAMEA SINGLE CELL MULTIOMICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 100.BRAZIL SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 101.BRAZIL SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 102.BRAZIL SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 103.BRAZIL SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 104.SAUDI ARABIA SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 105.SAUDI ARABIA SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 106.SAUDI ARABIA SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 107.SAUDI ARABIA SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 108.REST OF LAMEA SINGLE CELL MULTIOMICS MARKET, BY TYPE, 2020-2030
TABLE 109.REST OF LAMEA SINGLE CELL MULTIOMICS MARKET, BY APPLICATION, 2020-2030
TABLE 110.LAMEA SINGLE CELL MULTIOMICS MARKET, BY TECHNIQUE, 2020-2030
TABLE 111.REST OF LAMEA SINGLE CELL MULTIOMICS MARKET, BY END USER, 2020-2030
TABLE 112.10X GENOMICS: COMPANY SNAPSHOT
TABLE 113.10X GENOMICS: OPERATING SEGMENT
TABLE 114.10X GENOMICS.: PRODUCT PORTFOLIO
TABLE 115.10X GENOMICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 116.BD: COMPANY SNAPSHOT
TABLE 117.BD: OPERATING SEGMENTS
TABLE 118.BD: PRODUCT PORTFOLIO
TABLE 119.BD: KEY DEVELOPMENTS
TABLE 120.BERKELEY: COMPANY SNAPSHOT
TABLE 121.BERKELEY: OPERATING SEGMENTS
TABLE 122.BERKELEY: PRODUCT PORTFOLIO
TABLE 123.BERKELEY: KEY DEVELOPMENTS
TABLE 124.BGI GENOMICS: COMPANY SNAPSHOT
TABLE 125.BGI GENOMICS: PRODUCT PORTFOLIO
TABLE 126.BGI GENOMICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 127.BIORAD: COMPANY SNAPSHOT
TABLE 128.BIORAD: OPERATING SEGMENTS
TABLE 129.BIORAD: PRODUCT PORTFOLIO
TABLE 130.BIORAD: KEY DEVELOPMENTS
TABLE 131.DANAHER: COMPANY SNAPSHOT
TABLE 132.DANAHER: PRODUCT SEGMENTS
TABLE 133.DANAHER: PRODUCT PORTFOLIO
TABLE 134.DANAHER: KEY DEVELOPMENTS
TABLE 135.DOLOMITE: COMPANY SNAPSHOT
TABLE 136.DOLOMITE: OPERATING SEGMENTS
TABLE 137.DOLOMITE: PRODUCT PORTFOLIO
TABLE 138.DOLOMITE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 139.EPICYPHER: COMPANY SNAPSHOT
TABLE 140.EPICYPHER: OPERATING SEGMENTS
TABLE 141.EPICYPHER: PRODUCT PORTFOLIO
TABLE 142.EPICYPHER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 143.FLUIDIGM: COMPANY SNAPSHOT
TABLE 144.FLUIDIGM: OPERATING SEGMENTS
TABLE 145.FLUIDIGM: PRODUCT PORTFOLIO
TABLE 146.FLUIDIGM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 147.ILLUMINA: COMPANY SNAPSHOT
TABLE 148.ILLUMINA: OPERATING SEGMENT
TABLE 149.ILLUMINA: PRODUCT PORTFOLIO
TABLE 150.MILTENYI: COMPANY SNAPSHOT
TABLE 151.MILTENYI: OPERATING SEGMENTS
TABLE 152.MILTENYI: PRODUCT PORTFOLIO
TABLE 153.MISSION BIO: COMPANY SNAPSHOT
TABLE 154.MISSION BIO: OPERATING SEGMENTS
TABLE 155.MISSION BIO: PRODUCT PORTFOLIO
TABLE 156.MISSION BIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 157.NANOSTRING TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 158.NANOSTRING TECHNOLOGIES: OPERATING SEGMENTS
TABLE 159.NANOSTRING TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 160.NANOSTRING TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 161.OLINK: COMPANY SNAPSHOT
TABLE 162.OLINK: OPERATING SEGMENT
TABLE 163.OLINK.: PRODUCT PORTFOLIO
TABLE 164.OLINK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 165.PARSE: COMPANY SNAPSHOT
TABLE 166.PARSE: OPERATING SEGMENT
TABLE 167.PARSE: PRODUCT PORTFOLIO
TABLE 168.PARSE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 169.QIAGEN: COMPANY SNAPSHOT
TABLE 170.QIAGEN: OPERATING SEGMENT
TABLE 171.QIAGEN: PRODUCT PORTFOLIO
TABLE 172.QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 173.TAKARA HOLDINGS: COMPANY SNAPSHOT
TABLE 174.TAKARA HOLDINGS: PRODUCT PORTFOLIO
TABLE 175.TAKARA HOLDINGS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 176.THERMO FISHER: COMPANY SNAPSHOT
TABLE 177.THERMO FISHER: OPERATING SEGMENTS
TABLE 178.THERMO FISHER: PRODUCT PORTFOLIO
TABLE 179.THERMO FISHER: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 01.GLOBAL SINGLE CELL MULTIOMICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2022
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2022 (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2022
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF SINGLE CELL GENOMICS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF SINGLE CELL PROTEOMICS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF SINGLE CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF SINGLE CELL METABOLOMICS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF ONCOLOGY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF CELL BIOLOGY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF NEUROLOGY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF IMMUNOLOGY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF STEM CELL RESEARCH MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF SINGLE-CELL ISOLATION AND DISPENSING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF SINGLE-CELL ANALYSIS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF ACADEMIC INSTITUTES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF CONTRACT RESEARCH ORGANIZATIONS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF PHARMACEUTICAL AND BIOTECH COMPANIES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 27.10X GENOMICS: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.10X GENOMICS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 29.BD: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.BD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.BD: REVENUE SHARE BY REGION, 2020(%)
FIGURE 32.BERKELEY: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.BERKELEY: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.BERKELEY: REVENUE SHARE BY REGION, 2020(%)
FIGURE 35.BGI GENOMICS: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.BGI GENOMICS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 37.BIORAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.BIORAD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.BIORAD: REVENUE SHARE BY REGION, 2020(%)
FIGURE 40.DANAHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 42.DANAHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 43.FLUIDIGM: NET SALES, 2018–2020 ($MILLION)
FIGURE 44.FLUIDIGM: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 45.ILLUMINA: NET SALES, 2018–2020 ($MILLION)
FIGURE 46.ILLUMINA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 47.NANOSTRING TECHNOLOGIES: NET SALES, 2018–2020 ($MILLION)
FIGURE 48.NANOSTRING TECHNOLOGIES: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 49.QIAGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 50.QIAGEN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 51.QIAGEN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 52.TAKARA HOLDINGS: NET SALES, 2019–2021 ($MILLION)
FIGURE 53.TAKARA HOLDINGS: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 54.THERMO FISHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 55.THERMO FISHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 56.THERMO FISHER: REVENUE SHARE BY REGION, 2020(%)
This section provides the opinions of top level CXOs in the single cell multiomics market. According to the CXOs, new advances of single-cell technologies provide the opportunity to separate biological insights within individual cells. Single-cell sequencing technology is divided into genotypic and phenotypic, which help to determine the mechanisms to govern diseases and health. Furthermore, applications of single cell multiomics primarily include oncology, cell biology, neurology, stem cell, and immunology.
Furthermore, rise in technological advancements in single-cell analysis products and increase in number of large-scale genomics studies leveraging single-cell RNA Sequencing (sc-RNA) are expected to drive the market growth. Furthermore, increasing adoption of personalized medicine for screening and diagnostics of genetic disorders and rising disposable income in emerging economies drive the growth of the single cell multiomics market.
Moreover, North America is projected to account for a major share of the global single cell multiomics market during the forecast period. The market in the region is anticipated grow in the near future, owing to availability of developed healthcare infrastructure and continuous research activities for the development of advanced technologies. North America is expected to be followed by Europe during the forecast period. Moreover, Germany and UK are expected to grow at high CAGR in Europe single cell multiomics market.
A. The total market value of single cell multiomics market is $2,175.0 million in 2020.
A. The forecast period for single cell multiomics market is 2021 to 2030
A. The market value of single cell multiomics market in 2021 is $2,655.89 million.
A. The base year is 2020 in single cell multiomics market
A. Top companies such as are 10X Genomics, Inc., Becton, Dickinson and Company, Berkeley Lights Inc., BGI Genomics Co. Ltd, Bio Rad Laboratories, Inc., Danaher Corporation (Cytiva Life Sciences), Dolomite Bio, Epicypher Inc., Fluidigm Corporation, Illimina, Inc, Miltenyi Biotec B.V. & CO., Mission Bio, Inc., Nanostring Technologies, Inc., Olink Holding AB (Olink Proteomics), Parse Bioscience, Qiagen N.V., Takara Holdings Inc. (Takara Bio Group) and Thermo Fischer Scientific Inc., held a high market position in 2020.
A. Single cell genomics segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period due to advanced method of classifying individual cells that can define unique traits and identify rare cell typesand is thus expected to drive the segment
A. Increase in technological advancements in single-cell analysis products, surge in adoption of personalized medicine for screening and diagnostics of genetic disorders is anticipated to drive the market in the forecast period.
A. North America is projected to account for a major share of the global single cell multiomics market during the forecast period. U.S. dominated the North America single cell multiomics market owing to availability of developed healthcare infrastructure, presence of key players and continuous research activities for the development of advanced technologies across the country.
Start reading instantly.
This Report and over 68,113+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report